Marco Antônio De Bastiani

Marco Antônio De Bastiani

Auto-generated profile, based on publicly available information

Marco Antônio De Bastiani

Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
LMLiana M. de Medeiros
Liana M. de Medeiros
MBMarco A. De Bastiani
Marco A. De Bastiani
EREduardo P. Rico
Eduardo P. Rico
PSPatrícia Schonhofen
Patrícia Schonhofen
BPBianca Pfaffenseller
Bianca Pfaffenseller
FKFábio Klamt
Fábio Klamt

13 June 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
LML L da Motta
L L da Motta
ILI Ledaki
I Ledaki
KPK Purshouse
K Purshouse
SHS Haider
S Haider
MBM A De Bastiani
M A De Bastiani
AMA McIntyre
A McIntyre
The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.

10 August 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
PFPâmela C. L. Ferreira
Pâmela C. L. Ferreira
BBBruna Bellaver
Bruna Bellaver
CTCécile Tissot
Cécile Tissot
YWYi-Ting Wang
Yi-Ting Wang
TPTharick A. Pascoal
Tharick A. Pascoal
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD) patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like protein 1 (YKL-40) levels with brain amyloid-β (Aβ) and tau pathologies. We assessed 121 individuals across the aging and AD clinical spectrum with positron emission tomography (PET) brain imaging for Aβ ([18F]AZD4694) and tau ([18F]MK-6240), as well as CSF GFAP and YKL-40 measures. We observed that higher CSF GFAP levels were associated with elevated Aβ-PET but not tau-PET load. By contrast, higher CSF YKL-40 levels were associated with elevated tau-PET but not Aβ-PET burden. Structural equation modeling revealed that CSF GFAP and YKL-40 mediate the effects of Aβ and tau, respectively, on hippocampal atrophy, which was further associated with cognitive impairment. Our results suggest the existence of distinct astrocyte biomarker signatures in response to brain Aβ and tau accumulation, which may contribute to our understanding of the complex link between reactive astrogliosis heterogeneity and AD progression.

7 July 2023 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
GCGiovanna Carello-Collar
Giovanna Carello-Collar
BBBruna Bellaver
Bruna Bellaver
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
VRVanessa G. Ramos
Vanessa G. Ramos
EZEduardo Zimmer
Eduardo Zimmer

23 June 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
DVD. M. Vargas
D. M. Vargas
MBM. A. De Bastiani
M. A. De Bastiani
EZEduardo Zimmer
Eduardo Zimmer
FKFábio Klamt
Fábio Klamt
Alzheimer’s disease (AD) is a multifactorial and complex neuropathology that involves impairment of many intricate molecular mechanisms. Despite recent advances, AD pathophysiological characterization remains incomplete, which hampers the development of effective treatments. In fact, currently, there are no effective pharmacological treatments for AD. Integrative strategies such as transcription regulatory network and master regulator analyses exemplify promising new approaches to study complex diseases and may help in the identification of potential pharmacological targets. In this study, we used transcription regulatory network and master regulator analyses on transcriptomic data of human hippocampus to identify transcription factors (TFs) that can potentially act as master regulators in AD. All expression profiles were obtained from the Gene Expression Omnibus database using the GEOquery package. A normal hippocampus transcription factor-centered regulatory network was reconstructed using the ARACNe algorithm. Master regulator analysis and two-tail gene set enrichment analysis were employed to evaluate the inferred regulatory units in AD case-control studies. Finally, we used a connectivity map adaptation to prospect new potential therapeutic interventions by drug repurposing. We identified TFs with already reported involvement in AD, such as ATF2 and PARK2, as well as possible new targets for future investigations, such as CNOT7, CSRNP2, SLC30A9, and TSC22D1. Furthermore, Connectivity Map Analysis adaptation suggested the repositioning of six FDA-approved drugs that can potentially modulate master regulator candidate regulatory units (Cefuroxime, Cyproterone, Dydrogesterone, Metrizamide, Trimethadione, and Vorinostat). Using a transcription factor-centered regulatory network reconstruction we were able to identify several potential molecular targets and six drug candidates for repositioning in AD. Our study provides further support for the use of bioinformatics tools as exploratory strategies in neurodegenerative diseases research, and also provides new perspectives on molecular targets and drug therapies for future investigation and validation in AD.

1 July 2019 in Journal of Neurotrauma
Verified
Journal Article
Closed access
RCRandhall B. Carteri
Randhall B. Carteri
AKAfonso Kopczynski
Afonso Kopczynski
MRMarcelo Salimen Rodolphi
Marcelo Salimen Rodolphi
NSNathan Ryzewski Strogulski
Nathan Ryzewski Strogulski
MSMônia Sartor
Mônia Sartor
LPLuis Valmor Portela
Luis Valmor Portela
Traumatic brain injury (TBI) increases Ca 2+ influx into neurons and desynchronizes mitochondrial function leading to energy depletion and apoptosis. This process may be influenced by brain testosterone (TS) levels, which are known to decrease after TBI. We hypothesized that a TS-based therapy could preserve mitochondrial neuroenergetics after TBI, thereby reducing neurodegeneration. C57BL/6J mice were submitted to sham treatment or severe parasagittal controlled cortical impact (CCI) and were subcutaneously injected with either vehicle (VEH-SHAM and VEH-CCI) or testosterone cypionate (15 mg/kg, TS-CCI) for 10 days. Cortical tissue homogenates ipsilateral to injury were used for neurochemical analysis. The VEH-CCI group displayed an increased Ca 2+ -induced mitochondrial swelling after the addition of metabolic substrates (pyruvate, malate, glutamate, succinate, and adenosine diphosphate [PMGSA]). The addition of Na + stimulated mitochondrial Ca 2+ extrusion through Na + /Ca 2+ /Li + exchanger (NCLX) in VEH-SHAM and TS-CCI, but not in the VEH-CCI group. Reduction in Ca 2+ efflux post-injury was associated with impaired mitochondrial membrane potential formation/dissipation, and decreased mitochondrial adenosine triphosphate (ATP)-synthase coupling efficiency. Corroborating evidence of mitochondrial uncoupling was observed with an increase in H 2 O 2 production post-injury, but not in superoxide dismutase (SOD2) protein levels. TS administration significantly reduced these neuroenergetic alterations. At molecular level, TS prevented the increase in pTau Ser396 and alpha-Spectrin fragmentation by the Ca 2+ dependent calpain-2 activation, and decreased both caspase-3 activation and Bax/BCL-2 ratio, which suggests a downregulation of mitochondrial apoptotic signals. Search Tool for the Retrieval of Interacting Genes/Proteins database provided two distinct gene/protein clusters, “upregulated and downregulated,” interconnected through SOD2. Therefore, TS administration after a severe CCI improves the mitochondrial Ca 2+ extrusion through NCLX exchanger and ATP synthesis efficiency, ultimately downregulating the overexpression of molecular drivers of neurodegeneration.